Becton Dickinson & Co
BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 13/3018% above fair value
$215.42−1.05 (-0.49%)
Close on Nov 17, 2026Market cap $58.68BP/E 65.1Yield 1.93%
Becton Dickinson Observational Clinical Studies Started by Year
Observational Clinical Studies Started — BD & C.R. Bard
Periods
Becton Dickinson Observational Clinical Studies Started: 5 in FY2026, up 400.0% from a year earlier.
Latest, FY2026
5
Period ended Sep 30, 2026 (CY2026)
Change on a year earlier
+400.0%
1 in FY2025
History
12 years
Since FY2015
Sources
1
NIH ClinicalTrials.gov Registry — Becton Dickinson & C.R. Bard
Where the FY2026 figure comes from
Source: NIH ClinicalTrials.gov Registry — Becton Dickinson & C.R. Bard ↗
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Becton Dickinson Observational Clinical Studies Started, annual FY2015–FY2026 [Data set]. Compiled from Becton Dickinson SEC filings and investor materials. https://stockdatahq.com/stocks/bdx/kpis/ext-ct-observ
See every metric in the Becton Dickinson KPI table. Data updated Nov 7, 2026.
See a number that looks wrong?